Told he could die in just months, this 27-year-old is 'more positive about life now'An Israeli drone strike on a hospital compound in northern Gaza on Thursday killed a 16-year-old boy in a wheelchair and wounded at least 12 other people, including medical staff, the Gaza Health Ministry and the hospital director said. Kamal Adwan Hospital is one of the few hospitals still partially operating in the northernmost part of Gaza , where Israeli forces are pressing an offensive that has almost completely sealed off the area from humanitarian aid for two months. Earlier Thursday, the human rights group Amnesty International accused Israel of committing genocide in the Gaza Strip during its war with Hamas, saying it has sought to deliberately destroy Palestinians by mounting deadly attacks, demolishing vital infrastructure and preventing the delivery of food, medicine and other aid. Israel says it goes to great lengths to avoid harming civilians as it battles Hamas. Israel's war against Hamas has destroyed vast areas of Gaza and displaced 90% of the population of 2.3 million, often multiple times. The war began when Hamas-led militants stormed into southern Israel in October 2023, killing some 1,200 people, mostly civilians, and taking around 250 people hostage . Israel’s blistering retaliatory offensive has killed at least 44,500 Palestinians , more than half of them women and children, according to Gaza’s Health Ministry, which does not say how many of the dead were combatants. Israel says it has killed over 17,000 militants, without providing evidence. Here's the Latest: WASHINGTON -- Three U.S. service members were being evaluated for potential traumatic brain injuries following an attack near a base in eastern Syria this week, Pentagon press secretary Maj. Gen. Pat Ryder said Thursday. Ryder said U.S. Central Command is still evaluating who was behind the attack near Mission Support Site Euphrates, which prompted the U.S. to conduct counter strikes on Tuesday. At the time, the Pentagon said rockets and mortars had landed in the vicinity of the base. The U.S. has about 900 troops in Syria to conduct missions to counter the Islamic Stage group. By Lolita Baldor BEIRUT — Hezbollah chief Naim Kassem said in a televised speech on Friday that the Lebanese militant group will provide financial assistance to families whose homes were completely destroyed during the recent war with Israel. In addition to being an armed group, Hezbollah is also a political party and provides extensive social services. In his second speech since the ceasefire that ended the war between Hezbollah and Israel on Nov. 27, Kassem reiterated that the U.N. Resolution 1701 “is not a new agreement,” adding that it stipulates that “Israel must withdraw from all Lebanese territories.” “The agreement is limited to the area south of the Litani River and nothing else,” Kassem said. He also accused Israel of committing over 60 violations of the ceasefire . Seated against the backdrop of a banner reading “reconstruction campaign,” Kassem announced that Hezbollah, with support from Iran, will provide financial aid to families whose homes were completely destroyed during the war. Those in Beirut and its southern suburbs will receive $14,000, while families outside the capital will receive $12,000, covering annual rent and compensation for furniture, he said. For partially damaged homes, specialized committees will assess the damages, Kassem said. Commenting on Syria and the stunning offensive by jihadi insurgents in recent days, Kassem said Hezbollah “will stand alongside Syria to stop the aggression.” “The aggression against Syria is sponsored by America and Israel,” Kassem said. He did not specify whether Hezbollah would send fighters to Syria to join forces with the Syrian army. WASHINGTON — The Biden administration says it believes accusations by Amnesty International that Israel is committing genocide in Gaza are “unfounded” although it says human rights groups play a “vital role” in speaking to the consequences of the conflict. Deputy State Department spokesman Vedant Patel declined to comment Thursday about specifics in the report, saying he would “let Amnesty International speak to the details about it.” But, he said the administration continues to disagree with its conclusion, as it has with previous similar reports from other organizations. “As you’ve heard us say previously, we disagree with the conclusions of such a report,” Patel told reporters in Washington. “We have said previously and continue to find that the allegations of genocide are unfounded. But there continues to be a vital role that civil society organizations like Amnesty International and human rights groups and NGOs play in providing information and analysis as it relates to Gaza and what’s going on.” At the same time, he said the administration’s concern about the situation in Gaza also remains unchanged and urged Israel to do more to improve humanitarian conditions in Gaza. “We continue to stress at every turn that there is a moral and strategic priority for Israel to comply with international humanitarian law and that is something we’re going to continue to raise with partners in the region and directly with Israel,” Patel said. CAIRO — An Israeli drone strike on a hospital compound in northern Gaza killed a 16-year-old boy in a wheelchair and wounded at least 12 other people, including medical staff, the Gaza Health Ministry and the hospital director said. Story continues below video Dr. Hossam Abu Safiya said an Israeli drone deliberately targeted patients and staff at the entrance to the reception and emergency area of Kamal Adwan Hospital, killing Mahmoud Abu al-Aish, a patient being taken in a wheelchair to the radiology department. Abu Safiya spoke in a video he posted on social media, standing inside the hospital as doctors operated on a wounded man behind him, calling it, “The injured treating the injured.” Abu Safiya was wounded in his thigh and back by an Israeli drone strike on the hospital last month. Israel says it goes to great lengths to avoid harming civilians as it battles Hamas. Kamal Adwan Hospital has been struck multiple times over the past two months since Israel launched a fierce military operation in northern Gaza against Hamas militants. In October, Israeli forces raided the hospital, saying that militants were sheltering inside and arrested a number of people, including some staff. Hospital officials denied the claim. The United Nations humanitarian office estimates up to 75,000 people remain in the northern towns of Beit Hanoun, Beit Lahiya and the Jabaliya refugee camp. The area has been almost completely sealed off from humanitarian aid for two months and experts have warned that a famine may have set in . A medical relief team from the U.N. World Health Organization was able to reach Kamal Adwan Hospital on Monday, delivering 10,000 liters of fuel (2,640 gallons), blood supplies, essential medical items and food. The U.N. press office also said DEIR AL-BALAH, Gaza Strip — Palestinian mothers in Gaza are struggling to secure baby formula for their newborn children and are forced to resort to alternatives that aren't the best options for infants. The Health Ministry in Gaza reported Thursday a shortage in baby formula amid a lack of aid entering the besieged territory and high prices due to scarcity. If found in the market, one box of baby formula could cost up to $50, according to an Associated Press journalist. Ahmed al-Farra, director of the child and maternity department at Nasser Hospital in the southern city of Khan Younis, said in the video statement posted by the Health Ministry that Israeli forces have been denying the entry of baby formula to the Gaza Strip for around three months. He explained that some women in Gaza can’t breastfeed their babies due to their own malnutrition or illness and must resort to giving infants starch or dissolved herbs instead, which pose a health risk. One mother said in a video posted by the Health Ministry that she was feeding her baby crushed biscuits, ground rice, and Cerelac brand baby formula if available. Medical professionals often recommend waiting to feed a child solid foods until at least the age of six months. The amount of aid entering Gaza plunged in October, and hunger is widespread across the territory, even in central Gaza where aid groups have more access. Humanitarian organizations say Israeli restrictions, ongoing fighting and the breakdown of law and order make it difficult to deliver assistance. Israel has said it is working to increase the flow of aid. JERUSALEM — Israeli rights groups are calling on the government to stop the “forcible transfer” of Palestinians out of northern Gaza and for the displaced to be allowed to return home. A joint letter from five well-known groups says “this forcible transfer is being undertaken through direct attacks on the civilian population, threats of such attacks, and the creation of inhumane living conditions.” The letter was issued by Gisha, Adalah, HaMoked, the Association for Civil Rights in Israel and Physicians for Human Rights – Israel, groups based in Israel that advocate for Palestinian rights. Tens of thousands have fled Gaza’s northernmost governorate since Israel launched a military operation there in early October against Hamas militants. The United Nations humanitarian office estimates up to 75,000 people remain in the northern towns of Beit Hanoun, Beit Lahiya and the Jabaliya refugee camp. The area has been almost completely sealed off from humanitarian aid for two months and experts have warned that a famine may have set in . Israel has ordered repeated mass evacuations since the start of the war. Around 90% of Gaza’s population of 2.3 million people have fled, often several times . Hundreds of thousands are packed into sprawling tent camps along the coast, an Israeli-declared humanitarian zone where Israel has also carried out repeated strikes against what it says are militant targets. Moshe Yaalon, a former top Israeli general and defense minister, said last week that Israel was engaged in “ethnic cleansing” and other war crimes in northern Gaza. Amnesty International on Wednesday said Israel was committing genocide in Gaza . Israel has adamantly denied the allegations, saying it goes to great lengths to avoid harming civilians as it battles Hamas, which ignited the war with its Oct. 7, 2023 attack into Israel. CAIRO — Amnesty International accused Israel of committing genocide in the Gaza Strip during its war with Hamas, saying it has sought to deliberately destroy Palestinians by mounting deadly attacks, demolishing vital infrastructure and preventing the delivery of food, medicine and other aid. The human rights group released a report Thursday in the Middle East that said such actions could not be justified by Hamas’ Oct. 7, 2023, attack into Israel, which ignited the war, or the presence of militants in civilian areas. Amnesty said the United States and other allies of Israel could be complicit in genocide, and called on them to halt arms shipments. “Our damning findings must serve as a wake-up call to the international community: this is genocide. It must stop now,” Agnès Callamard, Secretary General of Amnesty International, said in the report. Israel, which was founded in the aftermath of the Holocaust, has adamantly rejected genocide allegations against it as an antisemitic “blood libel.” It is challenging such allegations at the International Court of Justice , and it has rejected the International Criminal Court’s accusations that Prime Minister Benjamin Netanyahu and his former defense minister committed war crimes in Gaza. “The deplorable and fanatical organization Amnesty International has once again produced a fabricated report that is entirely false and based on lies,” Israel’s Foreign Ministry said in a statement. Israel accused Hamas , which has vowed to annihilate Israel, of carrying out a genocidal massacre in the attack that triggered the war, and said it is defending itself in accordance with international law.Why Tesla Stock Jumped Again Todaymilyon88 net 。

The Latest Drag Race Down Under Queen Talks About The Tough Competition This Season49ers' visit gives Packers a chance to damage the playoff hopes of their postseason nemesis

Pride, bragging rights and more than $115M at stake when final college playoff rankings come out

North-East Gateway To Vast Southeast Asian Markets, Scindia Tells InvestorsIoT Node and Gateway Market Opportunities and Competitive Strategies 2024-2031

American Water Works Co. stock outperforms competitors on strong trading day

Bestow Named a Top 100 Financial Technology Company of 2024

Career Horoscope Today for December 04, 2024: Astro tips for working harder and achieving more

LOUISVILLE, Ky. (AP) — Louisville has approved a five-year contract extension through June 2030 for athletic director Josh Heird, whose 2 1/2-year tenure has included the hirings of two men’s basketball coaches and football coach Jeff Brohm. The university’s Board of Trustees on Thursday authorized President Kim Schatzel to execute the deal, three days after the University of Louisville Athletic Association board approved the agreement. Heird was named interim AD in December 2021 before being elevated to the full-time job the following June. Schatzel said in a release that the extension signals the school’s faith in Heird and added, “He is the right person and right leader” to take the athletic program forward to a bright future. Several significant personnel moves marked Heird’s initial tenure. He fired basketball coach Chris Mack in January 2022 and subsequently hired former Cardinals player Kenny Payne two months later. Heird fired Payne last March after two historically bad seasons and replaced him with Pat Kelsey on March 28. Heird also hired ex-Louisville quarterback and assistant Brohm in December 2022. The Cardinals won 10 games to reach the ACC championship game for the first time last season and are headed for a second consecutive postseason under the Louisville native with a berth in the Sun Bowl on Dec. 31 in El Paso, Texas. Heird has also extended contracts for women’s basketball coach Jeff Walz, volleyball coach Dani Busboom-Kelly and baseball coach Dan McDonnell. The AD’s other achievements include a $41 million naming rights deal for the Cardinal Stadium football field along with a $4 million club renovation. He also secured a $1 million donation to enhance Louisville's Jim Patterson Stadium baseball field. Heird also serves on the NCAA women’s basketball selection committee. AP sports: https://apnews.com/hub/apf-sports and https://twitter.com/AP_Sports

OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Dec 12, 2024-- Takeda ( TSE:4502/NYSE:TAK ) will host an investor R&D Day today beginning at 8:30 a.m. JST in Tokyo. The meeting will focus on programs in the company’s late-stage pipeline, the transformative value they could deliver to patients, and the market opportunities they represent. “We are focused on advancing our innovative pipeline and accelerating late-stage programs to deliver sustainable revenue growth to 2030 and beyond, building upon the strong momentum of our Growth and Launch Products,” said Christophe Weber, Takeda chief executive officer. “The first three Phase 3 programs will read out in 2025, initiating a cadence of potential filings across multiple indications over the next several years.” Eight Regulatory Filings in FY2025 – FY2029 The late-stage pipeline includes oveporexton (TAK-861), zasocitinib (TAK-279), rusfertide (TAK-121), mezagitamab (TAK-079), fazirsiran (TAK-999) and elritercept (TAK-226). Combined these programs have potential peak revenue 1 of $10B - $20B. Data from three Phase 3 programs is expected to read out in 2025: Filings for these three indications are expected in fiscal years 2025 and 2026. Five additional indication filings for late-stage programs are on pace for fiscal years 2027 through 2029: “Takeda has established an exciting, late-stage pipeline of transformative therapies that we believe will deliver value to our company and, most importantly, to the patients we serve around the world,” said Andy Plump, president of R&D at Takeda. “As we continue scaling our capabilities and maximizing R&D investment to deliver the late-stage pipeline, we are also progressing an exciting early-stage pipeline, supporting a cutting-edge research organization, and focusing on creative business development across our therapeutic areas to sustain Takeda’s future and continue to meet significant unmet patient needs.” 2024 R&D Day Agenda The meeting includes the following presentations and speakers: A Global, Innovation-Driven Biopharmaceutical Company Christophe Weber, President & CEO R&D Strategy and Pipeline Highlights Andy Plump, President, Research and Development Neuroscience: Deep-Dive on Orexin Franchise Sarah Sheikh, Head of Neuroscience Therapeutic Area Unit and Head of Global Development Ramona Sequeira, President of Global Portfolio Division Gastrointestinal and Inflammation: Deep-Dive on Zasocitinib, Rusfertide, Mezagitamab, Fazirsiran Chinwe Ukomadu, Head of Gastrointestinal and Inflammation Therapeutic Area Unit Ramona Sequeira, President of Global Portfolio Division Oncology: Deep-Dive on Elritercept – Newly Announced Business Development Deal Teresa Bitetti, President Global Oncology Business Unit P.K. Morrow, Head of Oncology Therapeutic Area Unit Webcast Details A live webcast of the meeting begins at 8:30 a.m. JST December 13 (6:30 p.m. EST December 12). Presentations are available on the Investor Relations section of Takeda’s website where a video replay will be available following the meeting. About Takeda Takeda is focused on creating better health for people and a brighter future for the world. We aim to discover and deliver life-transforming treatments in our core therapeutic and business areas, including gastrointestinal and inflammation, rare diseases, plasma-derived therapies, oncology, neuroscience and vaccines. Together with our partners, we aim to improve the patient experience and advance a new frontier of treatment options through our dynamic and diverse pipeline. As a leading values-based, R&D-driven biopharmaceutical company headquartered in Japan, we are guided by our commitment to patients, our people and the planet. Our employees in approximately 80 countries and regions are driven by our purpose and are grounded in the values that have defined us for more than two centuries. For more information, visit www.takeda.com . Important Notice For the purposes of this notice, “press release” means this document, any oral presentation, any question and answer session and any written or oral material discussed or distributed by Takeda Pharmaceutical Company Limited (“Takeda”) regarding this release. This press release (including any oral briefing and any question-and-answer in connection with it) is not intended to, and does not constitute, represent or form part of any offer, invitation or solicitation of any offer to purchase, otherwise acquire, subscribe for, exchange, sell or otherwise dispose of, any securities or the solicitation of any vote or approval in any jurisdiction. No shares or other securities are being offered to the public by means of this press release. No offering of securities shall be made in the United States except pursuant to registration under the U.S. Securities Act of 1933, as amended, or an exemption therefrom. This press release is being given (together with any further information which may be provided to the recipient) on the condition that it is for use by the recipient for information purposes only (and not for the evaluation of any investment, acquisition, disposal or any other transaction). Any failure to comply with these restrictions may constitute a violation of applicable securities laws. The companies in which Takeda directly and indirectly owns investments are separate entities. In this press release, “Takeda” is sometimes used for convenience where references are made to Takeda and its subsidiaries in general. Likewise, the words “we”, “us” and “our” are also used to refer to subsidiaries in general or to those who work for them. These expressions are also used where no useful purpose is served by identifying the particular company or companies. Forward-Looking Statements This press release and any materials distributed in connection with this press release may contain forward-looking statements, beliefs or opinions regarding Takeda’s future business, future position and results of operations, including estimates, forecasts, targets and plans for Takeda. Without limitation, forward-looking statements often include words such as “targets”, “plans”, “believes”, “hopes”, “continues”, “expects”, “aims”, “intends”, “ensures”, “will”, “may”, “should”, “would”, “could”, “anticipates”, “estimates”, “projects” or similar expressions or the negative thereof. These forward-looking statements are based on assumptions about many important factors, including the following, which could cause actual results to differ materially from those expressed or implied by the forward-looking statements: the economic circumstances surrounding Takeda’s global business, including general economic conditions in Japan and the United States; competitive pressures and developments; changes to applicable laws and regulations, including global health care reforms; challenges inherent in new product development, including uncertainty of clinical success and decisions of regulatory authorities and the timing thereof; uncertainty of commercial success for new and existing products; manufacturing difficulties or delays; fluctuations in interest and currency exchange rates; claims or concerns regarding the safety or efficacy of marketed products or product candidates; the impact of health crises, like the novel coronavirus pandemic, on Takeda and its customers and suppliers, including foreign governments in countries in which Takeda operates, or on other facets of its business; the timing and impact of post-merger integration efforts with acquired companies; the ability to divest assets that are not core to Takeda’s operations and the timing of any such divestment(s); and other factors identified in Takeda’s most recent Annual Report on Form 20-F and Takeda’s other reports filed with the U.S. Securities and Exchange Commission, available on Takeda’s website at: https://www.takeda.com/investors/sec-filings-and-security-reports/ or at www.sec.gov . Takeda does not undertake to update any of the forward-looking statements contained in this press release or any other forward-looking statements it may make, except as required by law or stock exchange rule. Past performance is not an indicator of future results and the results or statements of Takeda in this press release may not be indicative of, and are not an estimate, forecast, guarantee or projection of Takeda’s future results. Peak Sales and PTRS Estimates References in this press release to peak revenue potential ranges are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue potential ranges represent Takeda’s assessments of various possible future commercial scenarios that may or may not occur. References in this press release to PTRS are to internal estimates of Takeda regarding the likelihood of obtaining regulatory approval for a particular product in a particular indication. These estimates reflect the subjective judgment of responsible Takeda personnel and have been approved by Takeda’s Portfolio Review Committee for use in internal planning. Medical Information This press release contains information about products that may not be available in all countries, or may be available under different trademarks, for different indications, in different dosages, or in different strengths. Nothing contained herein should be considered a solicitation, promotion or advertisement for any prescription drugs including the ones under development. Elritercept license agreement Elritercept is included for reference only. Takeda entered into an exclusive license agreement with Keros for global rights, in all territories outside of mainland China, Hong Kong and Macau, to Elritercept. The closing of the transaction is subject to receipt of regulatory approval(s), expected in the first calendar quarter of 2025. Takeda does not currently have rights to Elritercept. ___________________________ 1 References in this presentation to peak revenue potential are estimates that have not been adjusted for probability of technical and regulatory success (PTRS) and should not be considered a forecast or target. These peak revenue ranges represent Takeda’s assessments of various possible future commercial scenarios that may or may not occur. View source version on businesswire.com : https://www.businesswire.com/news/home/20241211148492/en/ CONTACT: Investor Relations Christopher O’Reilly Christopher.oreilly@takeda.com +81 (0) 90-6481-3412 Takeda Media Relations media_relations@takeda.com KEYWORD: MASSACHUSETTS UNITED STATES JAPAN NORTH AMERICA ASIA PACIFIC INDUSTRY KEYWORD: ONCOLOGY HEALTH NEUROLOGY CLINICAL TRIALS PHARMACEUTICAL BIOTECHNOLOGY SOURCE: Takeda Pharmaceutical Company Limited Copyright Business Wire 2024. PUB: 12/12/2024 05:30 PM/DISC: 12/12/2024 05:30 PM http://www.businesswire.com/news/home/20241211148492/en

Pearl Diver Credit Company Inc. Prices Offering of Series A Preferred StockLOS ANGELES (AP) — LeBron James has been ruled out of the Los Angeles Lakers’ game at Minnesota on Friday night due to soreness in his left foot. James will miss his second straight game when the Lakers return from a four-day break to face the Timberwolves, the Lakers announced Thursday. The top scorer in NBA history was away from the team this week with an excused absence attributed to “personal reasons,” coach JJ Redick said Wednesday. It’s unclear whether James will even make the quick round trip to Minnesota before the Lakers’ next game at home against Memphis on Sunday. James missed his first game of his record-tying 22nd NBA season when the Lakers beat Portland at home last Sunday. That absence also was attributed to his foot injury. James is averaging 23.0 points, 9.1 assists and 8.0 rebounds for the Lakers (13-11), who have lost seven of 10 after a 10-4 start. The Lakers upgraded starter Austin Reaves to questionable for the game at Minnesota after he missed LA’s previous five games with a pelvic bruise. Anthony Davis is listed as probable with left plantar fasciitis. ___ AP NBA: https://apnews.com/NBA

Company's first ultra-low power AI module will be commercially available for wearables and various other battery-powered on-device AI applications starting Q1 2025 SANTA CLARA, Calif. , Dec. 16, 2024 /PRNewswire/ -- Ambient Scientific, The AI Processor Company, announced today its first coin cell battery powered AI module, named the Sparsh-board, targeted for a variety of on-device AI applications such as human activity recognition, voice control, acoustic event detection and more capable of running on a coin cell battery for months of always-on AI operation. Equipped with motion sensors, a digital microphone, BLE module and several other components, the Sparsh module is an extremely powerful and versatile module to enable rapid prototyping of a vast array of battery-powered AI applications. "While traditional MCUs force an undesirable tradeoff between AI performance and power consumption, our ultra-low power AI processor GPX10 ushers a paradigm shift with our groundbreaking analog in-memory computing technology," said GP Singh, Founder and CEO of Ambient Scientific. Product makers can now enable highly accurate and diverse AI applications without compromising on AI performance, battery life, form factor, flexibility and more. Ambient Scientific's exhaustive software stack makes the development of AI applications easier than ever before with support for industry standard AI frameworks such as Tensorflow and keras and a continuously evolving homegrown compiler, capable of supporting essentially all the major types of neural networks. With various sample AI applications and algorithms included, developers can get begin developing AI applications within minutes of downloading our AmbiSense SDK . Current applications being worked on cut across industries, including predictive maintenance, AI-enabled medical devices, wearables, voice controlled toys and more. With increasing demand from product makers, enthusiasts, students and researchers alike, Ambient Scientific plans to launch several reference designs for battery-powered AI applications and similar form factor modules to enable rapid prototyping and fulfill its mission to make AI computing efficient, accessible and affordable for all. Meet Ambient Scientific at CES 2025 Ambient Scientific is excited to unveil its Sparsh AI module at CES 2025 with live demostrations of AI applications running on coin cell batteries such as Fall Detection, voice recognition and more. To explore potential synergies, attendees can schedule meetings CES 2025 with Ambient Scientific at. To learn more about Ambient Scientific, visit our booth at CES 2025 or download our press kit . About Ambient Scientific Ambient Scientific is a fabless semiconductor company pioneering AI hardware and software design to create next-generation low-power processors for edge and on-device AI applications. With a team comprised of Ex-Sun Microsystems, Intel, Broadcom and Google professionals, Ambient Scientific is committed to bringing the power of AI to all, through cutting edge hardware and software products. To learn more about its products, visit www.ambientscientific.ai and follow Ambient Scientific on LinkedIn . Click here for more details about our booth at: https://ces25.mapyourshow.com/8_0/exhibitor/exhibitor-details.cfm?exhid=0013A00001egpuFQAQ . View original content to download multimedia: https://www.prnewswire.com/news-releases/ambient-scientific-unveils-first-ever-ai-module-powered-by-a-coin-cell-battery-302332996.html SOURCE Ambient Scientific, Inc.

Kendrick Lamar gave music listeners an early holiday present Friday with the surprise drop of a new album. The Grammy winner's 12-track "GNX" is his first release since 2022's "Mr. Morale & The Big Steppers" and his sixth studio album overall. It also comes just months after his rap battle with Drake. Lamar first teased the album with a cover art and video snippet of "GNX," which features multi-instrumentalist Jack Antonoff as a co-producer on every track except for "Peekaboo." Other notable producers include Sounwave and DJ Mustard, who both contributed production on the hit "Not Like Us," the ubiquitous diss track emanating from the Drake feud. Lamar's former Top Dawg Entertainment labelmate SZA appears on a couple songs including "Gloria" and "Luther," which also features sampled vocals from Luther Vandross and Cheryl Lynn through "If This World Were Mine." On the opening track "Wacced Out Murals," Lamar raps about cruising in his Buick GNX (Grand National Experimental) car with listening to Anita Baker. He brings up Snoop Dogg posting Drake's AI-assisted "Taylor Made Freestyle" diss track on social media and Nas congratulating Lamar for being selected to headline February's Apple Music Super Bowl Halftime Show in New Orleans. Lamar also shows admiration for Lil Wayne, who expressed his hurt feelings after being passed over as the headliner in his hometown. Lamar, 37, has experienced massive success since his debut album "good kid, m.A.A.d city" in 2012. Since then, he's accumulated 17 Grammy wins and became the first non-classical, non-jazz musician to win a Pulitzer Prize for his 2017 album "DAMN." The surprise release caps a big year for Lamar, who was featured on the song "Like That" with Future and Metro Boomin - a track that spent three weeks at No. 1 on the Billboard Hot 100 this year. Lamar is up for seven Grammys, fueled by "Not Like Us," which earned nods for record and song of the year, rap song, music video as well as best rap performance. He has two simultaneous entries in the latter category, a career first: "Like That" is up for best rap performance and best rap song, too.Gov. Murphy: 'Sophisticated systems' being used to look for drones in NJStock market today: Nasdaq hits a record as Wall Street drifts ahead of Federal Reserve's meetingPhoto courtesy of Jingo SAN FRANCISCO, Dec. 12, 2024 (GLOBE NEWSWIRE) -- Jingo, a new artificial intelligence (AI)-driven e-commerce marketplace , unveiled the launch of its anticipated referral program. This strategic initiative aims to accelerate user growth while rewarding loyal customers with substantial shopping credits. The program, running from December 6, 2024, to February 28, 2025, offers participants the chance to win significant prizes for successfully referring new users to the platform. The top referrer will receive an impressive $50,000 in shopping credits, while the second and third-place winners will be awarded $30,000 and $10,000 in credits, respectively. Jingo has garnered attention for its personalized shopping experiences, driven by innovative AI technology. The referral program represents a key milestone in the platform's journey toward transforming e-commerce. Rohan Bhanot, co-founder of Jingo, expressed enthusiasm about the program: " We are thrilled to launch this referral campaign as a way to thank our early adopters and encourage them to share the Jingo experience with friends and family. This program aligns perfectly with our goal to create a community-driven marketplace that understands and anticipates user needs." The platform has secured backing and investment from industry leaders with extensive experience at companies like Pinterest, Walmart, Minted, eBay, and other prominent technology and retail organizations. "We are so excited to have such an accomplished group of investors backing our goal. Their collective experience across technology, retail, and e-commerce will be invaluable as we work to change the online shopping experience," shares Ujjal Pathak, co-founder and chief executive officer (CEO) of Jingo. Program participation is straightforward: existing users share their unique referral code with potential new users. When referred individuals complete their first purchase, referrers earn credit toward the program's substantial prizes. The initiative welcomes participation from all users across the United States, with no state restrictions. "This referral campaign will drive user growth and improve the overall Jingo experience. As our user base expands, Buddy becomes even more intelligent and capable of providing hyper-personalized recommendations," adds Pathak. For more information about Jingo and its referral program, visit www.jingo.app . About Jingo Jingo is an innovative e-commerce platform transforming shopping into a hyper-personalized experience tailored to individual preferences. By leveraging advanced AI and data-driven insights, Jingo delivers product recommendations that align seamlessly with each user's unique tastes and needs. The company's mission is to make shopping a proactive and intuitive experience, fundamentally changing how people engage with commerce and technology. Jingo is supported by experts with deep experience across leading companies such as Pinterest, Walmart, Minted, eBay, Square, Nike, Klarna, and Intuit. This collective expertise drives its vision to set a new standard for personalization, connecting customers with the products they love while creating a smarter, more efficient shopping ecosystem. Contact information: Name: Ujjal Pathak Email: ujjal@jingo.app Company: Jingo Technologies Website: www.jingo.app A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/f3cada3e-418b-4133-9ce0-5e74219a7443 © 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.